Celgene, Recombinant Antibody Network deal

Celgene and the Recombinant Antibody Network (RAN) will develop next-generation antibody-based cancer therapies. Celgene will pay $25 million up front for the option to license therapies from RAN, a consortium of researchers from the University of California San Francisco (San Francisco, Calif.), University of Chicago (Chicago, Ill.) and University of Toronto (Toronto, Ontario). ...